AlphaTON, Cyncado announce LOI for tokenization for mesothelioma program

AlphaTON Capital (ATON), alongside its wholly owned oncology subsidiary Tarus Therapeutics dba Cyncado Therapeutics, announced a non-binding letter of intent to evaluate tokenization of single-indication economics for TT-4 in mesothelioma,. The company is leveraging decentralized science principles and web3 infrastructure to reimagine how life-saving medical research is funded, accelerated, and brought to patients globally. AlphaTON’s strategic vision unites the company’s comprehensive TON ecosystem operations – including validator services, network staking, and Telegram-based application development serving over one billion users – with Cyncado’s clinical-stage pipeline targeting immune checkpoint resistance in deadly cancers. Cyncado has confirmed it is in final clinical start-up preparations for TT-4, an oral, ultra-selective A2B receptor antagonist, with first-patient dosing targeted for Q1 2026. The drug will initially enter a safety dose-escalation cohort enrolling solid tumor patients under Cyncado’s existing FDA-cleared TT-10-101 protocol, with a larger mesothelioma-focused study planned immediately thereafter at major U.S. cancer centers.